DB19418InvestigationalProtein Based Therapies
Atisnolerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy).
- Also known as
- gamma4 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV1-8*03 (86.7%) -(IGHD) - IGHJ4*01 (93.3%), CDR-IMGT [8.8.13] (26-33.51- 58.97-109)) (1-120)-Homo sapiens IGHG4*01, G4v5 h P10, nG4m(a) CH2 L92 (CH1 (121-218), hinge 1-12 S10>P (228) (219-230), · immunoglobulin G4-kappa, anti-[Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1]
- Code names
- REGN5715
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Atisnolerbart, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account